Company intelligence / Profile preview

Aktiv Pharma Group

Broomfield, Colorado, United States

Ownership: Private
Employees: ~70
Development stage: Other

Overview

Aktiv Pharma Group has a diversified pipeline of emergency-use autoinjectors (TXA, atropine, pralidoxime chloride, scopolamine, and combinations), with several programs in late-stage development supported by US government contracts, as well as partnered biologic combination products utilizing glass-free container technology. Clinical results are not published, but products are advancing toward commercialization, particularly for government and emergency markets.

Therapeutic areas: HematologyNeurologyOther
Modalities: Small moleculeBiologicDeviceDrug-device combination product
Industry: Biotech

Partnerships

Undisclosed leading biopharmaceutical company (for biologics + ARCH platform)US government (multiple contracts, including Department of Defense)

Beyond the preview

Go deeper on Aktiv Pharma Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aktiv Pharma Group.

Explore the full profile